SCHEMBL2340443

SCHEMBL2340443

Nc1ncc(C2CCN(Cc3ccccc3)CC2)c(Nc2ccccc2)n1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.50
ALDH1A1 P00352 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
BCL6 P41182 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.47
DRD2 P14416 1/20 0.45
DRD4 P21917 1/20 0.45
DRD3 P35462 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
ACHE P22303 5/20 0.43
EGFR P00533 1/20 0.43
ERBB2 P04626 1/20 0.43
NSD2 O96028 1/20 0.42
SIGMAR1 Q99720 1/20 0.41
BCHE P06276 2/20 0.41
BRS3 P32247 1/20 0.41
ROCK1 Q13464 1/20 0.41
BACE1 P56817 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL73760 0.83 HRH3 (0.53) HRH3DRD2DRD4DRD3MEN1
Trifluoroacetic Acid SCHEMBL3778498 0.75 CHRM4 (0.47) HRH3DRD2DRD4DRD3MEN1
SCHEMBL5066413 0.73 MEN1 (0.50) HRH3ALDH1A1DRD2DRD4DRD3
SCHEMBL6981484 0.71 DRD2 (0.58) HRH3ALDH1A1L3MBTL1DRD2DRD4
SCHEMBL6045689 0.70 MEN1 (0.62) ALDH1A1DRD2DRD4DRD3MEN1
SCHEMBL13490551 0.70 DRD2 (0.52) HRH3DRD2DRD4DRD3MEN1
SCHEMBL2588250 0.68 MEN1 (0.65) DRD2DRD4DRD3MEN1KMT2A
SCHEMBL7583523 0.67 MEN1 (0.58) ALDH1A1L3MBTL1DRD2DRD4DRD3
SCHEMBL19846671 0.67 BCL6 (1.00) ALDH1A1BCL6EGFRROCK1
SCHEMBL27471275 0.67 MEN1 (0.66) ALDH1A1DRD2DRD4DRD3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2089384-B1 2-(PIPERIDIN-4-YL)-4-PHENOXY-OR PHENYLAMINO-PYRIMIDINE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS HOFFMANN LA ROCHE (CH) 2015-08-05 EP disclosed
US-7998969-B2 enzyme inhibitors such as 4-[2-(1-Benzyl-piperidin-4-ylamino)-pyrimidin-4-yloxy]-3,5-dimethyl-benzonitrile, used in combination with other viricides, for preventing and treatment of viral infections such as HIV, AIDS and AIDS related diseases ROCHE PALO ALTO LLC (US) 2011-08-16 US disclosed
US-20080146595-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146595-A1 Non-nucleoside reverse transcriptase inhibitors NQO2, SAMHD1, POLR2A HRH3 1471/4885ALDH1A1 396/4885L3MBTL1 1645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.